Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VIRX

Viracta Therapeutics Inc

Dec 13 • 04:00PM ET

0.2027

Dollar change +0.0129
Percentage change 6.80	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX CRSP GILD BHVN FATE INCY KPTI ARGX EXEL NBIX

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.10	Insider Own	29.53%	Shs Outstand	39.74M	Perf Week	28.70%
Market Cap	8.61M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	0.00%	Shs Float	28.01M	Perf Month	29.03%
Income	-43.29M	PEG	-	EPS next Q	-0.16	Inst Own	13.00%	Short Float	5.63%	Perf Quarter	-11.87%
Sales	0.00M	P/S	-	EPS this Y	35.23%	Inst Trans	-36.96%	Short Ratio	0.75	Perf Half Y	-69.92%
Book/sh	-0.17	P/B	-	EPS next Y	35.09%	ROA	-97.94%	Short Interest	1.58M	Perf Year	-57.77%
Cash/sh	0.50	P/C	0.41	EPS next 5Y	-	ROE	-370.13%	52W Range	0.13 - 1.31	Perf YTD	-64.44%
Dividend Est.	-	P/FCF	-	EPS past 5Y	44.96%	ROI	-	52W High	-84.53%	Beta	0.67
Dividend TTM	-	Quick Ratio	0.76	Sales past 5Y	134.94%	Gross Margin	-	52W Low	54.14%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	0.76	EPS Y/Y TTM	10.59%	Oper. Margin	-	RSI (14)	61.36	Volatility	18.33% 13.94%
Employees	40	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	3.25
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	18.11%	Payout	-	Rel Volume	0.35	Prev Close	0.19
Sales Surprise	-	EPS Surprise	-1.24%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	2.10M	Price	0.20
SMA20	25.22%	SMA50	5.12%	SMA200	-60.67%	Trades		Volume	726,815	Change	6.80%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-16-24	Downgrade	Leerink Partners	Outperform → Market Perform	$5 → $3
Feb-01-22	Initiated	RBC Capital Mkts	Outperform	$10
May-03-21	Initiated	H.C. Wainwright	Buy	$35
Apr-26-21	Initiated	SVB Leerink	Outperform	$18
Mar-25-21	Initiated	Evercore ISI	Outperform	$45

Nov-13-24 07:00AM	Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.09%
Nov-06-24 04:30PM	Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma (GlobeNewswire)
Sep-03-24 07:00AM	Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +11.42%
Aug-14-24 07:05AM	Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -18.31%
07:00AM	Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan (GlobeNewswire)
07:40AM	Loading…
Jun-11-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +6.00%
Jun-07-24 07:22AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-17-24 04:05PM	Viracta Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
May-14-24 07:00AM	Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer (GlobeNewswire)
May-09-24 10:54PM	VIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -7.88%
04:05PM	Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 06:00AM	3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck (InvestorPlace)
May-07-24 04:05PM	Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
Apr-15-24 08:00AM	Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma (GlobeNewswire) -32.17%
Apr-01-24 08:30AM	Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan (GlobeNewswire) +8.82%
08:51AM	Loading…
Mar-08-24 08:51AM	VIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
Mar-07-24 04:05PM	Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -11.92%
Feb-29-24 08:00AM	Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial (GlobeNewswire) -8.43%
Feb-06-24 04:05PM	Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -9.37%
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-04-24 08:00AM	Viracta Therapeutics Provides Clinical Update and Outlook for 2024 (GlobeNewswire)
Dec-12-23 08:00AM	Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma (GlobeNewswire) -6.28%
Dec-04-23 08:30AM	Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels (GlobeNewswire)
Nov-09-23 08:30AM	Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -14.70%
Nov-07-23 04:15PM	Viracta Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +19.17%
Oct-04-23 07:00AM	Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers (GlobeNewswire) -10.68%
Sep-05-23 09:00AM	Viracta Therapeutics to Host R&D Day on October 4, 2023 (GlobeNewswire)
Aug-18-23 04:05PM	Viracta Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
Aug-14-23 08:00AM	Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-08-23 08:30AM	Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma (GlobeNewswire)
07:30AM	Loading…
Aug-07-23 07:30AM	Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire) -6.67%
Jun-28-23 08:00AM	Viracta Therapeutics Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL) (GlobeNewswire) +5.59%
May-31-23 04:15PM	Viracta Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +6.02%
May-17-23 09:50AM	2 Strong Buy Penny Stocks With Over 400% Upside on the Horizon (TipRanks) +37.35%
May-11-23 04:05PM	Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-08-23 04:05PM	Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates (GlobeNewswire) -11.00% +20.22%
May-02-23 04:05PM	Viracta Therapeutics Announces Departure of Chief Medical Officer (GlobeNewswire) -8.13%
Apr-19-23 04:30PM	Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days (GlobeNewswire)
Mar-13-23 04:05PM	Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Mar-08-23 04:05PM	Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference (GlobeNewswire)
Feb-07-23 04:05PM	Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-19-23 08:30AM	Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma (GlobeNewswire)
Jan-08-23 01:00PM	Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives (GlobeNewswire)
Nov-30-22 06:10PM	Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-21-22 05:08PM	Viracta Therapeutics Announces New Employment Inducement Grant (GlobeNewswire) -6.18%
Nov-14-22 04:41PM	Viracta Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
Nov-10-22 04:05PM	Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs (GlobeNewswire) -9.20%
Nov-02-22 04:05PM	Viracta Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-19-22 04:30PM	Viracta Therapeutics Announces New Employment Inducement Grant (GlobeNewswire) -8.44% -9.98%
08:00AM	Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth (PR Newswire)
Sep-07-22 09:00AM	Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma (PR Newswire) +11.86%
Aug-16-22 04:15PM	Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases (PR Newswire) -7.24%
Aug-11-22 09:00AM	Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors (PR Newswire) +9.21%
Aug-09-22 08:30AM	Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates (PR Newswire) -12.15%
Aug-01-22 08:19AM	What Kind Of Shareholders Hold The Majority In Viracta Therapeutics, Inc.'s (NASDAQ:VIRX) Shares? (Simply Wall St.)
Jun-13-22 04:15PM	Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award (PR Newswire) -7.30% -5.51%
Jun-02-22 08:30AM	Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting (PR Newswire)
Jun-01-22 04:15PM	Viracta Therapeutics to Present at the Jefferies Healthcare Conference (PR Newswire)
May-23-22 08:00AM	Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman (GlobeNewswire)
May-13-22 04:05PM	Viracta Therapeutics Announces New Employment Inducement Grant (PR Newswire) +13.90%
May-11-22 04:05PM	Viracta Therapeutics to Present at Upcoming May Investor Conferences (PR Newswire) -11.69% -6.37%
May-10-22 04:05PM	Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates (PR Newswire)
Apr-20-22 11:58AM	Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors (PR Newswire)
Apr-07-22 10:13AM	Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-18-22 04:10PM	Viracta Therapeutics Announces New Employment Inducement Grant (PR Newswire) +6.43%
Mar-09-22 04:30PM	Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference (PR Newswire) +5.76%
Feb-22-22 11:35AM	What Type Of Shareholders Own The Most Number of Viracta Therapeutics, Inc. (NASDAQ:VIRX) Shares? (Simply Wall St.)
Feb-10-22 09:00AM	Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (PR Newswire) +9.12%
Feb-08-22 09:48AM	2 Strong Buy Penny Stocks That Could Rally to $10 (or More) (TipRanks) +8.04%
Jan-31-22 08:30AM	Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors (PR Newswire) +11.20%
Jan-04-22 09:00AM	Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (PR Newswire) -6.39%
Dec-16-21 08:30AM	Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index (PR Newswire)
Dec-13-21 07:15PM	Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021 (PR Newswire) -9.05% -10.99%
11:30AM	Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021 (PR Newswire)
Nov-29-21 08:00AM	Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma (PR Newswire) -5.58%
Nov-10-21 08:00AM	Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (PR Newswire)
Nov-05-21 09:00AM	Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance (PR Newswire)
Nov-04-21 09:00AM	Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 American Society of Hematology Annual Meeting (PR Newswire)
Nov-01-21 04:05PM	Viracta Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Oct-06-21 08:00AM	Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors (PR Newswire)
Sep-07-21 08:00AM	Viracta Therapeutics to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-23-21 08:00AM	Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China (PR Newswire) +6.95%
Aug-16-21 08:00AM	Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, to its Board of Directors (PR Newswire) -10.43%
Aug-12-21 08:00AM	Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (PR Newswire)
Jul-21-21 08:00AM	Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors (PR Newswire)
Jul-06-21 08:00AM	Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team (PR Newswire) -6.02%
Jun-28-21 08:00AM	Viracta Therapeutics Announces its Addition to the Russell 2000® Index and other FTSE Russell Indexes (PR Newswire)
Jun-01-21 08:00AM	Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma (PR Newswire)
May-25-21 07:46AM	What Kind Of Shareholders Hold The Majority In Viracta Therapeutics, Inc.'s (NASDAQ:VIRX) Shares? (Simply Wall St.) +6.23%
May-18-21 04:05PM	Viracta Therapeutics to Host Key Opinion Leader Webinar (PR Newswire) +6.46%
May-12-21 04:05PM	Viracta Therapeutics Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates (PR Newswire) -16.65%
Apr-29-21 06:01AM	Analysts Bet on These 2 Biotech Stocks; See Over 50% Upside Potential (TipRanks)
Apr-08-21 08:00AM	Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-23-21 08:00AM	Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction (PR Newswire) -5.09%
Mar-11-21 08:00AM	Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference (PR Newswire) +7.73%
Mar-04-21 08:00AM	Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team (PR Newswire) -18.30%
Mar-03-21 08:00AM	Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference (PR Newswire)

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROYSTON IVOR	Director	Nov 25 '24	Option Exercise	0.00	25,219	0	839,741	Nov 27 04:08 PM
Pomerantz Roger	Director	Nov 25 '24	Option Exercise	0.00	9,034	0	126,478	Nov 27 04:06 PM
ROYSTON IVOR	Director	Aug 25 '24	Option Exercise	0.00	25,219	0	814,522	Sep 12 06:13 PM
Pomerantz Roger	Director	Aug 25 '24	Option Exercise	0.00	9,034	0	117,444	Sep 12 06:10 PM
Pomerantz Roger	Director	May 25 '24	Option Exercise	0.00	9,035	0	108,410	May 29 07:12 PM
ROYSTON IVOR	Director	May 25 '24	Option Exercise	0.00	25,219	0	789,303	May 29 07:07 PM
ROYSTON IVOR	Director	Feb 25 '24	Option Exercise	0.00	25,219	0	764,084	Feb 27 07:58 PM
Pomerantz Roger	Director	Feb 25 '24	Option Exercise	0.00	9,034	0	99,375	Feb 27 07:56 PM
Chevallard Daniel R.	CFO and COO	Feb 25 '24	Option Exercise	0.00	6,889	0	105,711	Feb 27 07:54 PM
Chevallard Daniel R.	CFO and COO	Feb 27 '24	Sale	0.73	3,405	2,493	102,306	Feb 27 07:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VIRX

Viracta Therapeutics Inc

Upgrade your FINVIZ experience